web analytics
17.7 C
Munich
Monday, May 10, 2021

GenViro Buzz Puts Decision Diagnostics Corp (OTCMKTS: DECN) Back on Track

Decision Diagnostics Corp (OTCMKTS: DECN) has been moving steadily higher in recent days on steady accumulation from Investors. DECN traded as low as $0.05 after the suspension but has now come back to the level it traded at beforehand. The stock is once again emerging as a volume leader already topping $1 million in dollar volume today even with the skull & crossbones designation from otcmarkets.

The Company said on Friday it has filed a provisional patent for its Genviro! Swift Professional product titled, “Method and Apparatus for Swift Determination of the Covid-19 Virus.” In so doing, the company is unveiling its Hematocrit adjustment feature, initially developed for its GenUltimate TBG system.

Decision Diagnostics Corp (OTCMKTS: DECN) is an 18-year old, diabetes and now disease testing bio-technology development firm. DECN’s products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $15+ billion at-home testing market. The company’s GenUltimate TBG product is not yet available for sale in the United States or Puerto Rico but is for sale in select International markets since late February 2020.

DECN has run up the charts as the Company unveils its GenViro(TM) Corona Virus Screening Kit which “provides results in 15 seconds, based on a small finger prick blood sample.” The company’s methodology employs a simple, easy to use, swift (15 seconds and faster than Rapid) method for determining the presence of a virus in blood lyced into blood plasma. Blood sample requirements are 1-2 microliters. DECN designed and tested the kit in Daegu, South Korea already and therefore are confident of the success of their kit application testing for the FDA.

Microcapdaily has been covering DECN since the stock was $0.03. We stated on March 3 when DECN first started moving “Decision Diagnostics Corp (OTCMKTS: DECN) is on a fast rise after the Company announced its new screening methodology for the Coronavirus (Covid19). According to DECN the product is timely, simple to use, cost effective and will be commercial ready in the summer of 2020.

To Find out the inside Scoop on DECN Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

DECN

On June 12 DECN announced its continued support for additional COVID-19 testing on a worldwide level, as the company prepares a Second Amendment to its Emergency Use Application (EUA) that was completed and first submitted to the FDA on April 3, 2020.

This Amendment specifically addresses what the company believes are positive changes in the FDA Guidance and/or platforms (EUA updates 4 and 5) initiated on May 4 and May 11, 2020, respectively. The company believes that both of these guidance additions/changes help us as we present our GenViro! Swift :15 Kit and prepare it for commercial sale in anticipation of securing regulatory approval. In addition, the company emphasizes its ongoing support for increased testing as the US is experiencing a substantial uptick in the number of Covid-19 infections in approximately 20 states and the critical need to increase testing worldwide.

Keith Berman CEO of DECN commented on June 17 “With these new developments and as great a sense of urgency as we have faced to date from this virus, we have reason to expect action from the FDA. We have recently received a written commitment for the distribution of our GenViro! Swift Kits from a previously referenced distributor who will represent the product in India, Singapore, Malaysia and Indonesia, and in recent negotiations we have come to an agreement on distribution of GenViro! Swift kits in Thailand, Vietnam, Nepal, Bangladesh, Sri Lanka, and Australia. We will discuss this in greater length is subsequent announcements.”

We have a Monster Pick Coming. Subscribe Right Now!

Currenly trading at a $66 million market valuation DECN has recently come back into the trading range it was at before the suspension. The stock still carries the dreaded skull and crossbones designation from otcmarkets. According to DECN its GenViro(TM) Corona Virus Screening Kit easily tops anything on the market; GenViro! provides results in 15 seconds, based on a small finger prick blood sample. The method is safe, effective, and its biggest benefit to the healthcare system is that the device can be used to screen out the 97% or 98% of those tested that are negative for COVID-19. Microcapdaily has been covering DECN since the stock was .o3. We will be updating on DECN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with DECN.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in DECN either long or short and we have not been compensated for this article.

More articles

2 COMMENTS

  1. You better have a strong look at GNBT they FINUALLY pased phase 11 testing after 9 years and 480 patients.But the have the best. Cov 19 products ready to go see website

  2. GenViro by Decision Diagnostics will be a game changer and will corner the market when it comes to testing for the virus and subsequent viruses. It is on the right track and has seen and will continue to grow exponentially. I currently hold shares and recommend this to as a excellent opportunity since stock Price is way undervalued. Thanks

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.